お知らせ • May 13
Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026 Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026. お知らせ • Feb 28
Nippon Shokubai Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026 Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026 お知らせ • Nov 18
Nippon Shokubai Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026 Nippon Shokubai Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 05, 2026 お知らせ • Aug 14
Nippon Shokubai Co., Ltd. to Report Q2, 2026 Results on Nov 07, 2025 Nippon Shokubai Co., Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025 お知らせ • Jul 31
Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 5,000,000 shares, representing 3.3% for ¥7,000 million. Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 3.3% of its issued share capital (excluding treasury stock), for a total purchase price of ¥7,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 27, 2026. As of June 30, 2025, the company has 151,691,868 issued shares (excluding treasury stock) and 4,308,132 treasury shares. お知らせ • Jun 26
Nippon Shokubai's U.S. Group Company Acquires Iscc Plus Certification for Acrylic Acid and Superabsorbent Polymers Nippon Shokubai Group companies in the United States have acquired ISCC PLUS certification for acrylic acid (hereinafter "AA") and superabsorbent polymers (hereinafter "SAP") produced locally. This enables Nippon Shokubai group to globally supply AA and SAP with a carbon footprint considered net zero. Through promoting the use of ISCC PLUS-certified AA and SAP, NipponShokubai Group aims to contribute to reducing environmental impact across the supply chain and to advancing a circular economy. Toward carbon neutrality by 2050, Nippon ShokubAI Group will continue to implement the "transformation" outlined in its long-term vision and mid-term management plan to enhance customer value. Nippon Shokubia Group commits and declares its compliance with the ISCC PLUS requirements in accordance with the latest ISCC regulations. ISCC (International Sustainability and Carbon Certification): It is a third-party certification program developed by International Sustainability and Carbon Certification (ISCC) system GmbH based in Germany to manage and guarantee sustainable raw materials and products such as biomass and recycled materials in the supply chain. Carbon footprint considered net zero: ISCC PLUS-certified products incorporate the biogenic CO2 removal associated with biomass growth into their carbon footprint calculations. The carbon footprints of these products are considered effectively net zero through the proportionally offset based on the share of biomass-derived feedstock allocated using the mass balance method. The mass balance method: When biomass-derived and petroleum-derived raw materials are used together in production, the proportion of biomass input can be allocated to specific end products. This method is officially recognized under the ISCC PLUS certification system. お知らせ • Jun 24
Nippon Shokubai Plans to Expand Its Gmp-Compliant Nucleic Acid Drug API Manufacturing Capacity Tenfold Nippon Shokubai CO., LTD. has announced a plan to expand its GMP (1)-compliant manufacturing capacity for nucleic acid drug "active pharmaceutical ingredients" (APIs) tenfold in response to rapidly growing global demand in the nucleic acid drug market. Nucleic acid drugs are generally defined as "chemically synthesized drugs with oligonucleotides as active ingredients that exert their effects without being translated into proteins." As a new modality following small molecule and antibody drugs, they are expected to be applied in areas such as rare diseases, neurological disorders, and cancers -- fields where conventional treatments have been limited. The capacity expansion will involve the installation of a large-scale production line with ten times the capacity (several kilograms per batch) of the company's existing line. The new facility is scheduled to begin operation in 2027, making it one of Japan's largest CDMOs, capable of manufacturing nucleic acid drug APIs for common diseases that require large-scale supply. The company will strengthen its manufacturing system to meet a wide range of needs, from non-clinical stages to large-scale commercial production. Leveraging Nippon Shokubai's long-standing expertise in organic synthesis and rigorous quality control systems, the company manufactures oligonucleotides and peptides, which are medium-sized molecule APIs. Its GMP-compliant facilities, among the most advanced in Japan, have been audited and visited by multiple pharmaceutical companies, all of which have given high evaluations, establishing Nippon ShokubAI's strong reputation in the industry. The company will continue to provide flexible contract manufacturing services that meet diverse needs and contribute to a sustainable society by ensuring a stable supply of medium-sized molecule APIs that support human health and life. お知らせ • May 31
Nippon Shokubai Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025 Nippon Shokubai Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025 お知らせ • Apr 02
Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation. Nippon Shokubai Co., Ltd. (TSE:4114) agreed to acquire Emulsion Technology Co.,Ltd. from JSR Corporation for ¥7.2 billion on November 12, 2024. As part of consideration, ¥7.2 billion is paid towards common equity of Emulsion Technology Co.,Ltd.
For the period ending March 31, 2024, Emulsion Technology Co.,Ltd. reported total revenue of ¥13.3 billion, EBIT of ¥918 million and net income of ¥647 million.
The expected completion of the transaction is April 1, 2025.
Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation on April 1, 2025. お知らせ • Feb 06
Nippon Shokubai Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025 Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2025 results at 3:00 PM, Tokyo Standard Time on May 13, 2025 お知らせ • Dec 12
Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd. Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd. on December 9, 2024.
Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Lilac Pharma Co., Ltd. on December 9, 2024. お知らせ • Nov 11
Nippon Shokubai Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025 Nippon Shokubai Co., Ltd. announced that they will report Q3, 2025 results at 3:00 PM, Tokyo Standard Time on Feb 06, 2025 お知らせ • Aug 15
Nippon Shokubai Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024 Nippon Shokubai Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024 お知らせ • May 15
Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024 Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024. お知らせ • May 14
Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 4,000,000 shares, representing 2.59% for ¥5,000 million. Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 2.59% of its issued share capital (excluding treasury stock), for a total purchase price of ¥5,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in
response to change in the business environment. The program will be valid till February 28, 2025. As of March 31, 2024, the company has 154,642,750 issued shares (excluding treasury stock) and 1,357,240 treasury shares. お知らせ • Mar 02
Nippon Shokubai Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024 Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2024 results on May 13, 2024